Banner 20  20home 20page
Logo

Elysium Therapeutics, Inc.

Disrupting the $10B opioid pain market by doing what others thought impossible, creating safer opioid meds that protect against oral abuse and fatal overdose.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Danville, CA, USA
  • Currency USD
  • Founded May 2013
  • Employees 3
  • Incorporation Type C-corp
  • Website elysiumrx.com

Company Summary

Elysium Therapeutics, Inc. is a highly cost-efficient, primarily grant-funded company developing technologies to disrupt the $10B+ prescription opioid market. Our technologies could (i) prevent fatal overdoses, saving thousands of lives annually; (ii) preclude oral abuse of Rx opioids, and disrupt heartbreaking and often lethal progression to fentanyl and heroin use and addiction; and (iii) provide safe, highly-effective pain relief to patients.

Team

  • Default avatar
    A. Gregory Sturmer
    President and Chief Executive Officer

    Greg is a healthcare executive with over 25 years of strategic and operational experience. Before founding Elysium, Greg was CFO of Signature Therapeutics, where he raised over $60M. Previously, Greg was VP, Finance & Investor Relations at Theravance. Greg was responsible for strategic planning & investor relations from start-up through IPO. He was directly involved in negotiating two landmark deals with GSK that support its ~$4B valuation.

  • Default avatar
    Thomas E Jenkins
    EVP and Chief Scientific Officer

    Tom has more than 20 years experience in the pharmaceutical industry. Before founding Elysium, Tom co-founded Theravance, Inc. then later Signature Therapeutics where he was CSO and primary inventor of all of their technologies and product candidates. Tom led a small, highly productive research team that advanced several compounds through hPOC and attracted $80M in financing. Tom is a recognized leader in opioid abuse-resistance technologies.

Advisors

  • Default avatar
    Wilson, Sonsini, Goodrich & Rosati
    Lawyer
    Unconfirmed
    Default avatar
    Scott Morrison (Ernst & Young)
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Mid-Atlantic Bio Angels
    Unconfirmed